Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Restructuring Costs (2022 - 2025)

Historic Restructuring Costs for BridgeBio Pharma (BBIO) over the last 4 years, with Q3 2025 value amounting to $8.8 million.

  • BridgeBio Pharma's Restructuring Costs rose 9132.22% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 2779.87%. This contributed to the annual value of $15.6 million for FY2024, which is 9688.37% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Restructuring Costs of $8.8 million as of Q3 2025, which was up 9132.22% from $805000.0 recorded in Q2 2025.
  • BridgeBio Pharma's Restructuring Costs' 5-year high stood at $22.7 million during Q1 2022, with a 5-year trough of $272000.0 in Q3 2023.
  • In the last 4 years, BridgeBio Pharma's Restructuring Costs had a median value of $3.5 million in 2023 and averaged $5.2 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Restructuring Costs tumbled by 9457.74% in 2023, and later surged by 159889.71% in 2024.
  • Quarter analysis of 4 years shows BridgeBio Pharma's Restructuring Costs stood at $7.7 million in 2022, then plummeted by 90.2% to $754000.0 in 2023, then soared by 522.41% to $4.7 million in 2024, then skyrocketed by 88.39% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $805000.0 for Q2 2025, and $570000.0 during Q1 2025.